Table 1.
Association of ferredoxin 1 (FDX1) expression with clinicopathological characteristics in patients with clear cell renal cell carcinoma.
| Characteristic | Low expression of FDX1 | High expression of FDX1 | p |
|---|---|---|---|
| n | 269 | 270 | |
| T stage, n (%) | 0.019 | ||
| T1 | 121 (22.4%) | 157 (29.1%) | |
| T2 | 38 (7.1%) | 33 (6.1%) | |
| T3 | 103 (19.1%) | 76 (14.1%) | |
| T4 | 7 (1.3%) | 4 (0.7%) | |
| N stage, n (%) | 0.191 | ||
| N0 | 117 (45.5%) | 124 (48.2%) | |
| N1 | 11 (4.3%) | 5 (1.9%) | |
| M stage, n (%) | 0.090 | ||
| M0 | 210 (41.5%) | 218 (43.1%) | |
| M1 | 47 (9.3%) | 31 (6.1%) | |
| Pathologic stage, n (%) | 0.011 | ||
| Stage I | 118 (22%) | 154 (28.7%) | |
| Stage II | 30 (5.6%) | 29 (5.4%) | |
| Stage III | 70 (13.1%) | 53 (9.9%) | |
| Stage IV | 50 (9.3%) | 32 (6%) | |
| Primary therapy outcome, n (%) | 0.059 | ||
| PD | 8 (5.4%) | 3 (2%) | |
| SD | 1 (0.7%) | 5 (3.4%) | |
| PR | 1 (0.7%) | 1 (0.7%) | |
| CR | 49 (33.3%) | 79 (53.7%) | |
| Gender, n (%) | 0.005 | ||
| Female | 77 (14.3%) | 109 (20.2%) | |
| Male | 192 (35.6%) | 161 (29.9%) | |
| Histologic grade, n (%) | 0.011 | ||
| G1 | 5 (0.9%) | 9 (1.7%) | |
| G2 | 105 (19.8%) | 130 (24.5%) | |
| G3 | 107 (20.2%) | 100 (18.8%) | |
| G4 | 49 (9.2%) | 26 (4.9%) | |
| Age, n (%) | 0.897 | ||
| <= 60 | 133 (24.7%) | 136 (25.2%) | |
| > 60 | 136 (25.2%) | 134 (24.9%) | |
| Age, median (IQR) | 61 (53, 72) | 60 (51, 69) | 0.273 |